Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 27, 2015 7:10 AM ET

Pharmaceuticals

Company Overview of ProteoTech, Inc.

Company Overview

ProteoTech, Inc., also known as Proteoglycan Technologies, Inc., operates as a drug development company in the United States. The company offers therapeutics and diagnostics for amyloid diseases. Its products include Exebryl-1, a molecule compound to prevent the formation and accumulation of the soluble and insoluble forms of beta-amyloid protein, as well as amyloid plaques found in Alzheimer's brains of disease victims; PeptiClere, a nasal spray for the treatment of Alzheimer's disease; Synuclere for the treatment of Parkinson's disease; and Systebryl, a small molecule compound for the treatment of systemic amyloidosis associated with type 2 diabetes. ProteoTech, Inc. was founded in 1996 an...

12040 115th Avenue NE

Kirkland, WA 98034

United States

Founded in 1996

Phone:

425-823-0400

Fax:

425-823-8508

Key Executives for ProteoTech, Inc.

Chief Executive Officer and Director
Founder, President, Chief Scientific Officer and Director
Chief Operations Officer, Chief Financial Officer and Director
Chief Medical Officer
Age: 69
Director of Intellectual Property
Compensation as of Fiscal Year 2014.

ProteoTech, Inc. Key Developments

ProteoTech Announces Management Appointments

ProteoTech reported that Roger S. Flugel, Ph.D. has been appointed as Chief Executive Officer. Dr. Flugel has also been elected as a Director on the company's Board of Directors. Prior to joining ProteoTech, Dr. Roger Flugel was the CEO of TheraVida from 2007 to 2013, and before that, was a Principal with Sanderling Ventures, where he served in a variety of roles as Director, Chairman, CEO, or board observer at several of their portfolio companies.

ProteoTech Inc. Appoints Roger S. Flugel as Chief Executive Officer and Director

ProteoTech Inc. announced that Roger S. Flugel has been appointed as Chief Executive Officer. Dr. Flugel has also been elected as a Director on the company’s Board of Directors. Prior to joining ProteoTech, Dr. Roger Flugel was the CEO of TheraVida, Inc. (Mountain View, CA) from 2007 to 2013. Dr. Flugel is now responsible for representing ProteoTech in all business transactions and partnerships.

ProteoTech, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:30 AM

ProteoTech, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 09:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
Endo Finance Co. United States
New Orleans Center for Clinical Research, Inc. United States
BPT Pharmaceuticals Inc. United States
Solaris Therapeutics, Inc. United States
Rhodia Chirex America, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ProteoTech, Inc., please visit www.proteotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.